- Home
- NAII vs SLGL Comparison
NAII vs SLGL Comparison
Compare NAII & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAII
- SLGL
- Stock Information
- Founded
- NAII 1980
- SLGL 1997
- Country
- NAII United States
- SLGL Israel
- Employees
- NAII N/A
- SLGL N/A
- Industry
- NAII Medicinal Chemicals and Botanical Products
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- NAII Health Care
- SLGL Health Care
- Exchange
- NAII Nasdaq
- SLGL Nasdaq
- Market Cap
- NAII 21.1M
- SLGL 19.3M
- IPO Year
- NAII 1987
- SLGL 2018
- Fundamental
- Price
- NAII $3.25
- SLGL N/A
- Analyst Decision
- NAII
- SLGL Buy
- Analyst Count
- NAII 0
- SLGL 1
- Target Price
- NAII N/A
- SLGL $40.00
- AVG Volume (30 Days)
- NAII 4.8K
- SLGL 24.6K
- Earning Date
- NAII 05-14-2025
- SLGL 08-15-2025
- Dividend Yield
- NAII N/A
- SLGL N/A
- EPS Growth
- NAII N/A
- SLGL N/A
- EPS
- NAII N/A
- SLGL N/A
- Revenue
- NAII $125,483,000.00
- SLGL $12,103,000.00
- Revenue This Year
- NAII N/A
- SLGL N/A
- Revenue Next Year
- NAII N/A
- SLGL $31.17
- P/E Ratio
- NAII N/A
- SLGL N/A
- Revenue Growth
- NAII 4.39
- SLGL 603.66
- 52 Week Low
- NAII $2.57
- SLGL $3.34
- 52 Week High
- NAII $6.88
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- NAII 45.04
- SLGL 54.46
- Support Level
- NAII $3.21
- SLGL $7.28
- Resistance Level
- NAII $3.49
- SLGL $7.48
- Average True Range (ATR)
- NAII 0.10
- SLGL 0.33
- MACD
- NAII -0.03
- SLGL 0.02
- Stochastic Oscillator
- NAII 12.90
- SLGL 43.30
About NAII Natural Alternatives International Inc.
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.